A66 (also known as A-66) is a small molecule drug developed by the pharmaceutical company Ambit Biosciences. It is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a class of enzymes that play a critical role in the regulation of cell growth and survival. A66 is currently being studied as a potential treatment for various types of cancer.
Chemical name: The chemical name of A66 is N-(2-methylpropyl)-5-((5-(morpholinomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)pyridine-3-carboxamide.
Molecular formula: The molecular formula for A66 is C23H26F3N5O2.
Formula weight: The formula weight for A66 is 471.48 g/mol.
CAS No: The CAS number for A66 is 1166227-08-2.
Top Ten Keywords and Synonyms:
Synonyms: A-66; A 66; N-(2-Methylpropyl)-5-((5-(morpholinomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)pyridine-3-carboxamide
Health Benefits of A66: A66 is designed to inhibit the activity of PI3K, which is known to be overactive in many types of cancer cells. By inhibiting PI3K, A66 may help to slow or stop the growth of cancer cells, potentially leading to tumor regression and improved patient outcomes.
Potential Effects of A66: Preclinical studies have shown that A66 can inhibit the growth of various types of cancer cells, including breast, lung, and colon cancer cells. Additionally, A66 has been shown to induce apoptosis (cell death) and autophagy (a process by which cells degrade and recycle their own components) in cancer cells.
Product Mechanism: A66 works by targeting and inhibiting the activity of PI3K, an enzyme that plays a key role in the regulation of cell growth and survival. The inhibition of PI3K by A66 leads to reduced activation of downstream signaling pathways, including the AKT pathway, which is known to promote cell growth and survival. This results in decreased cancer cell proliferation and increased sensitivity to chemotherapy and radiation therapy.
Safety: As with any new drug, the safety of A66 is being carefully evaluated in clinical trials. Preliminary studies suggest that A66 is generally well-tolerated, with manageable side effects.
Side Effects: Common side effects of A66 include fatigue, nausea, vomiting, and diarrhea. Less common but more serious side effects may include low white blood cell count, liver damage, and heart problems.
Dosing Information: The appropriate dose of A66 depends on several factors, including the patient's age, weight, and overall health status. Dosage and duration of treatment are determined by the treating physician.
Conclusion: A66 is a promising new drug under investigation for the treatment of various types of cancer. By inhibiting the activity of PI3K, it has the potential to slow or stop the growth of tumors, potentially improving patient outcomes. While the drug is still in clinical trials, preliminary studies suggest that it is generally well-tolerated with manageable side effects. As research continues, A66 may represent an exciting new option for patients with cancer
